3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
9
Gemcitabine
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Paclitaxel
6
Cisplatin
6
Trastuzumab
5
Irinotecan
5
Doxorubicin
5
Docetaxel
5
Peripheral Blood Stem Cell Transplantation
4
Filgrastim
4
Capecitabine
4
poly ICLC
3
pazopanib
3
liposomal doxorubicin
3
durvalumab
3
atezolizumab
3
Therapeutics
3
Taxes
3
Surveys and Questionnaires
3
Radiation
3
Polymerase Chain Reaction
3
Oncolytic Virotherapy
3
Letrozole
3
Injections
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
tinostamustine
×
Sarcoma
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts